Bremelanotide weight loss research is early. Two small 2022 trials in women with obesity found modest short-term drops in weight and calorie intake. A 2025 trial then tested it with tirzepatide. TelosRX reviews what the studies actually found.
Most people know bremelanotide as PT-141, a peptide studied for sexual desire. Fewer know it has also been tested for appetite and body weight.
That second line of research is real, but it's small and short. This review walks through each study on bremelanotide weight loss, what it measured, and what it can't tell you yet.
One thing up front: bremelanotide is not FDA-approved for weight loss. Compounded PT-141 is not FDA-approved for any use. TelosRX does not prescribe PT-141 for weight management.
Bremelanotide Weight Loss Research at a Glance
| Study | Who | Design | Length | Main finding |
|---|---|---|---|---|
| Study A (published 2022) | 58 women with obesity | Phase 1, randomized, placebo-controlled | 15 days of dosing | Greater weight reduction and lower daily calorie intake vs placebo |
| Study B (published 2022) | 27 women with obesity | Phase 1 crossover, placebo-controlled | Three 4-day periods | Twice-daily dosing reduced calorie intake and weight vs placebo |
| BMT-801 (2024–2025) | Adults with obesity | Phase 2, randomized, double-blind, with tirzepatide | About 8 weeks of randomized dosing | Sponsor-reported additional weight loss with the combination; full peer-reviewed data pending |
| Setmelanotide (context) | Rare genetic obesity | Different MC4R drug, FDA-approved | Long-term | Shows the MC4R pathway can affect weight in specific conditions |
Why Would a Libido Peptide Affect Weight?
Bremelanotide activates melanocortin receptors in the brain. These are signaling switches tied to several body functions.
The one that matters here is MC4R (melanocortin 4 receptor). It sits in brain areas that help regulate hunger and energy balance. Turning it on tends to increase feelings of fullness.
Researchers have known about MC4R's role in appetite for decades. People born with faulty MC4R signaling often have severe early-onset obesity. That's why scientists wanted to see if an MC4R agonist (a drug that switches the receptor on) could reduce eating.
Bremelanotide was not designed as a weight drug. Its approved brand, Vyleesi, is FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Weight effects are a separate research question. For background on the peptide itself, see our explainer on what PT-141 is and how bremelanotide works.
Finding 1: Study A Showed Short-Term Weight and Calorie Reductions
The main published evidence comes from a paper in Diabetes, Obesity and Metabolism in 2022. It reported two phase 1 trials. You can read the full paper on PubMed Central.
In Study A, 58 women with obesity were randomized to bremelanotide or placebo. Injections were given under the skin three times daily for 15 days.
What the researchers reported:
- Body weight: the bremelanotide group had a significantly greater weight reduction than placebo by day 16. The average difference was about 1.3 kg.
- Calorie intake: average daily intake was lower with bremelanotide on every study day. The gap was roughly 400 calories per day.
- Completion: 27 of 30 women on bremelanotide finished the trial.
Those are statistically significant results. But context matters. This was a two-week study in a controlled setting. It tells us the drug can reduce eating in the short term. It does not tell us what happens over months.
Finding 2: Study B Tested Once- vs Twice-Daily Dosing
Study B used a crossover design. That means each participant rotated through different treatments, with washout breaks between them.
Women received placebo, a once-daily dose, or a twice-daily dose. Each period lasted four days, with a five-day washout in between.
- Twice-daily dosing: weight change over four days was significantly greater than placebo.
- Once-daily dosing: weight change was numerically greater than placebo, but not statistically significant.
- Calorie intake: both bremelanotide regimens reduced total calorie intake vs placebo.
Only 15 of 27 participants completed all three phases. Six withdrew under the study's blood pressure criteria, including two on placebo. Small numbers and dropouts make the results harder to generalize.
The authors' own conclusion was cautious. They wrote that MC4R agonist activity "may aid" in reducing calorie intake and weight in women with obesity.
Finding 3: Side Effects in the Weight Trials Matched Known PT-141 Effects
The tolerability picture in these trials looked familiar. It mirrored what earlier sexual-health trials reported.
| Effect | Study A: placebo | Study A: bremelanotide | Study B: bremelanotide arms |
|---|---|---|---|
| Nausea | 14.3% | 30.0% | 18–20% |
| Flushing | 0% | 13.3% | 15–18% |
| Blood pressure | Small, transient changes in Study A; some Study B withdrawals under BP criteria | ||
Figures above come from the 2022 paper linked earlier. Nausea and flushing are the two effects people most often report with bremelanotide. We cover them in more depth in our guide to PT-141 side effects.
Blood pressure deserves attention. Melanocortin agonists can cause short-lived rises in blood pressure. The Vyleesi label carries warnings about this. Anyone with uncontrolled high blood pressure or heart disease needs a careful provider review.
Finding 4: BMT-801 Tested Bremelanotide With Tirzepatide
The newest research pairs bremelanotide with tirzepatide, a GLP-1/GIP medication. The trial is called BMT-801. It's registered as NCT06565611 on ClinicalTrials.gov.
The idea is simple. GLP-1 drugs and MC4R agonists act on appetite through different routes. Researchers want to know if combining them adds benefit.
The study is phase 2, randomized, double-blind and placebo-controlled. It compared bremelanotide plus tirzepatide against each drug alone and placebo, over roughly eight weeks of randomized dosing.
In early 2025, the sponsor announced topline results. It reported that the combination produced more weight loss than placebo and met its primary endpoint. It also reported that a low-dose bremelanotide arm limited weight regain after tirzepatide was stopped.
Here's the honest caveat. These are sponsor-reported topline numbers. At the time of our review, we could not find a full peer-reviewed publication of the results. Until one appears, read the claims as preliminary.
What would make the combination result more convincing? A few things. A peer-reviewed paper with full methods would help. So would longer follow-up, data on muscle versus fat loss, and a clear safety readout.
Researchers would also want to know how dose affects the picture. Most people on tirzepatide move up in dose over months. Whether an MC4R add-on still matters at higher doses is an open question.
The sponsor has also described an oral MC4R compound in early preclinical work. Preclinical means animal or lab studies. Those results rarely translate directly to people.
Finding 5: The MC4R Pathway Works for Some Genetic Conditions
A different MC4R agonist, setmelanotide (brand Imcivree), offers useful context. It is FDA-approved for chronic weight management in specific rare genetic conditions.
These include certain POMC, PCSK1 or LEPR deficiencies and Bardet-Biedl syndrome. In these people, the brain's hunger-control pathway is broken upstream of MC4R.
Setmelanotide's approval shows that switching on MC4R can affect weight in the right patients. It does not prove bremelanotide will work the same way in common obesity. The two drugs differ in receptor selectivity, dosing and testing history.
How to Read These Studies
Study labels tell you a lot about how much weight to give a result. Here's a quick decoder.
- Phase 1: early human testing. The main goals are safety, dosing and first signs of effect. Groups are small.
- Phase 2: larger tests of whether a drug works for a specific use. Still short and not definitive.
- Phase 3: large, longer trials that regulators rely on for approval. Bremelanotide has none for weight.
- Randomized: people are assigned to groups by chance. This limits bias.
- Placebo-controlled: one group gets an inactive look-alike. It shows what changes without the drug.
- Crossover: each person tries more than one treatment in turn. Fewer people are needed, but carryover effects are possible.
- Topline results: a sponsor's first summary of key outcomes. Full methods and data usually come later.
By that scale, the bremelanotide weight evidence sits at phase 1 and early phase 2. That's the stage where many promising ideas still fall short.
It's also worth noting who ran the studies. The 2022 trials were conducted by the drug's developer. Industry funding is common and not a flaw by itself. Still, independent replication adds confidence, and it hasn't happened yet for weight outcomes.
Why Short Trials Can Mislead
A two-week weight change can look impressive. But early weight loss often includes water and gut contents, not just fat.
Appetite drugs also face adaptation. The body may push back over time through hunger signals and lower energy use. Only long trials show whether an effect holds.
Tolerability changes the picture too. A drug that causes nausea can reduce eating for that reason alone. Separating a true fullness effect from a "feel unwell, eat less" effect needs careful study design.
What the Bremelanotide Weight Loss Research Doesn't Show
It's easy to read a press headline and assume more than the data support. Here's what remains unknown.
- Long-term results. The published trials lasted days to weeks, not months.
- Effects in men. The two published weight trials enrolled women only.
- Durability. No published data show whether any weight change lasts after stopping.
- Best dose for weight. Study A used three daily injections. That's different from how PT-141 is used for sexual health.
- Head-to-head comparisons. There's no published trial comparing bremelanotide alone with a GLP-1 medication for weight.
- Safety at scale. Larger, longer trials are needed to judge blood pressure and other effects with repeated daily use.
Bottom line: the evidence suggests a short-term appetite effect. It does not establish bremelanotide as a weight-loss medication.
How This Compares With GLP-1 Evidence
The gap in evidence is large. GLP-1 medications like semaglutide and tirzepatide have been studied in large trials lasting a year or more. Several are FDA-approved for chronic weight management.
| Factor | Bremelanotide for weight | Approved GLP-1 medications |
|---|---|---|
| Largest published trials | Dozens of participants | Thousands of participants |
| Trial length | Days to weeks | One year or longer |
| FDA status for weight | Not approved | Several brands approved |
| Main mechanism | MC4R activation in the brain | GLP-1 (and GIP) receptor activation |
| Typical dosing studied | Multiple daily injections | Weekly injection or daily pill |
If weight management is your goal, the better-studied path is a GLP-1 medication. You can read about tirzepatide at TelosRX. Any prescription is subject to medical approval by a licensed provider through an asynchronous online review.
What This Means for You
If you're curious about PT-141, its studied and approved use is sexual desire, not weight. Any appetite change is a side observation, not a reason to start it.
If you're already on a GLP-1 and have heard about "adding PT-141," be cautious. Combination use outside a trial has not been shown to be safe or effective. Don't stack medications without talking to your provider first.
The differences between brand and compounded versions also matter. Our article on bremelanotide vs Vyleesi vs compounded PT-141 explains what each name means.
Interested in PT-141 for its studied use? Learn about PT-141 at TelosRX. Compounded PT-141 is not FDA-approved, and access is subject to medical approval by a licensed provider.
Questions to Ask Your Provider
If you're weighing any appetite or weight option, these questions keep the conversation grounded.
- What evidence supports this option for my specific goal?
- Is it FDA-approved for this use, or would it be off-label or compounded?
- How would it interact with medications I already take?
- What side effects should I watch for, and when should I report them?
- How will we measure whether it's working?
A good provider will welcome these questions. At TelosRX, the provider reviews your intake asynchronously and may follow up with questions before any decision.
Frequently Asked Questions
Does bremelanotide cause weight loss?
Small studies suggest it can reduce appetite and body weight in the short term. Two 2022 phase 1 trials in women with obesity found lower calorie intake and greater weight reduction than placebo over days to weeks. Long-term results are unknown. Bremelanotide is not FDA-approved for weight loss, and individual results vary.
How does PT-141 affect appetite?
PT-141 activates melanocortin receptors in the brain, including MC4R. MC4R helps regulate hunger and fullness. Switching it on tends to increase satiety, which may lower how much people eat. That's the proposed reason bremelanotide reduced calorie intake in early weight trials. The effect has only been studied over short periods.
Is PT-141 used with tirzepatide?
Only in research so far. The BMT-801 phase 2 trial tested bremelanotide together with tirzepatide in adults with obesity. The sponsor reported positive topline results in 2025, but full peer-reviewed data were not available at our review. Combining these medications outside a trial is not established as safe or effective.
Is bremelanotide FDA-approved for weight loss?
No. The brand Vyleesi is FDA-approved only for acquired, generalized HSDD in premenopausal women. It has no approved weight indication. Compounded PT-141 is not FDA-approved for any use. A different MC4R drug, setmelanotide, is approved for weight management in certain rare genetic conditions.
What are the side effects of bremelanotide in weight studies?
The most common effects were nausea and flushing, matching what sexual-health trials reported. In Study A, nausea occurred in 30% of bremelanotide users vs about 14% on placebo. Small, short-lived blood pressure changes were also monitored. Anyone with heart disease or high blood pressure needs careful provider screening first.
Can men use PT-141 for weight loss?
There's no published weight-loss data in men. The two published weight trials enrolled women only. PT-141 is not approved for weight management in anyone. If you're a man interested in PT-141 for its studied sexual-health use, any prescription is subject to medical approval by a licensed provider.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.